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Highly reactive bis-cyclooctyne-modiﬁed
diarylethene for SPAAC-mediated cross-linking†
Alexander V. Strizhak,a,b Krishna Sharma, a Oleg Babii,c Sergii Afonin, c
Anne S. Ulrich, c,d Igor V. Komarov *e,f and David R. Spring *a
Photoisomerizable diarylethenes equipped with triple bonds are promising building blocks for construct-
ing bistable photocontrollable systems. Here we report on the design, synthesis and application of a
cross-linking reagent which is based on a diarylethene core and features two strained cyclooctynes. High
reactivity of the cyclooctyne rings in catalyst-free 1,3-dipolar cycloaddition reactions was suggested to
stem from the additional strain imposed by the fused thiophene rings. This hypothesis was conﬁrmed by
quantum chemical calculations.
Introduction
Reversibly photoisomerizable diarylethene (DAE) units have
been inserted in countless molecules and systems, whose pro-
perties and functions can be controlled with light.1 DAEs
undergo pericyclic transformations under irradiation with UV
or visible light (Fig. 1). The “open” and “closed” photoforms
are stable at ambient temperatures that makes them attractive
for numerous applications, especially in biology and
medicine.1i,j,m,o
One of the popular synthetic approaches utilizes functiona-
lized DAE-derived reagents (“building blocks”) for modular
construction of photocontrollable molecules. For example, bis-
diethynyl-substituted diarylethene 1 (Fig. 2) has been proposed
as an entry to new photochromic DAE materials through palla-
dium-catalyzed Sonogashira cross-coupling reaction2 or for
Cu-catalysed cycloaddition to azides (a “click”-reaction) invol-
ving its triple bonds.3
We were interested in 1 and similar compounds because
they could be used for cross-linking the azide-substituted side
chains in biologically active peptides in order to stabilize their
conformation via so-called “stapling”. This could be done, for
example, using a two-component strategy, employing the click-
reaction.4 Stapling can increase the biostability, improve
binding aﬃnities and pharmacokinetic properties of pep-
tides,5 and photoisomerizable cross-linkers can additionally
make their bioactivities photocontrollable – a feature which is
attracting much interest due to potential applications in bio-
technology and medicine.1i,j,o
Cross-linking of peptides with azobenzene-derived, mainly
thiol-reactive photoisomerizable cross-linkers was extensively
studied since the beginning of 2000th. Eﬃcient photocontrol
of peptide conformation,6a–i folding,6j,k and aﬃnity of binding
to DNA6l,m was documented. It was demonstrated that biologi-
cally relevant processes like protein–protein interaction
(PPI)6n–q and insulin secretion6r could be “switched on” and
“switched oﬀ” reversibly with the use of the azobenzene-
derived cross-linked peptides. Photoisomerizable spiropyrane6s
and rhodopsin-like fragments6t were also utilized in peptide
cross-linkers to enable the photocontrol of peptide confor-
mation and properties. These studies have laid the ground for
the development of practically useful photocontrollable bio-
logically active compounds for biotechnology and in vivo
applications.1i
Fig. 1 Diarylethene fragment used in photocontrollable molecules and
systems, R1, R2 = alkyl; R3, R4 = H, alkyl, aryl; Y = S, O or N. The core unit
undergoing photoinduced pericyclic transformations is highlighted in
red.
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DAE-derived peptide cross-linkers are much less studied.
The only proof-of-principle experiment demonstrating success-
ful photocontrol of peptides stapled by the DAE building block
2 have been reported for DNA-binding peptides (Fig. 2).6u The
activated carboxylic groups in 2 reacted with the amino groups
of ornithine side chains to form amide bonds in the stapled
peptides. To the best of our knowledge, no DAE building
blocks equipped for a click-reaction have been used so far for
peptide stapling. In this paper, we report on the design and
synthesis of such a building block, and its validation for
peptide stapling applications.
Of particular interest for applications are bio-orthogonal
cross-linking reagents utilizing the strain-promoted azide–
alkyne cycloaddition (SPAAC) as the click-reaction, which avoids
toxic Cu-catalysts (Fig. 3).7 SPAAC has already been successfully
used for peptide stapling: a cyclooctadiyne derivative 3 (Fig. 2)
was employed as the stapling reagent and demonstrated excel-
lent performance.8 Here, we aimed at developing a DAE-based
cross-linking building block suitable for the Cu-free SPAAC.
Results and discussion
Design of the target compound
The utility of SPAAC in biological systems critically depends on
the reactivity of the strained alkynes involved in the reaction:
more reactive reagents can address faster biological processes
and can react with the azide-modified biomolecules even if
they are present at low concentrations in living systems. After
the pioneering work describing relatively slow-reacting cyclo-
octynes,7a much eﬀort was put into the development of stable,
but more reactive fluoro- and difluoro-substituted analogues,7b
heteroatom-containing cyclooctynes,7e dibenzo-annulated
cyclooctadiynes9 and twisted systems10 (see a recent review11).
When designing our DAE-based building block, we were
inspired by a recent report demonstrating that the addition of
one mole of azide to dibenzo[a,e]cyclooctadiyne 3 made the
second triple bond 500-fold more reactive.12a This can be
attributed to additional strain imposed on the medium-sized
carbocycle by the annulation of the five-membered triazole
ring, resulting in the enhanced reactivity of the remaining
triple bond. An exceptionally high reactivity was also reported
for compound 4, a cyclooctyne mono-annulated to a five-mem-
bered pyrrole ring.12b Taking into account these findings and
aiming at enhanced reactivity of our reagent, we targeted struc-
ture 5 (Fig. 2), in which two cyclooctyne residues are symmetri-
cally annulated to the five-membered thiophene rings of the
DAE fragment. Comparing to the known DAE-derived building
block 2, compound 5 will form less conformationally flexible
cross-linker (due to the presence of two additional cycles)
which might help to better convey its structural changes to the
cross-linked molecular unit upon photoisomerization.
Synthesis
The key intermediate in our synthesis of 5 was the cyclohepta-
none derivative 6 (Fig. 4). This compound is easily available
through the technically simple 1,1,1,3,3,3-hexafluoro-2-propa-
nol-promoted intramolecular Friedel–Crafts acylation reaction
of 7, as described for its non-methyl-substituted analogue.13
Compound 7 was obtained in good yield starting from
2-methyl-4-bromothiophene 8, following the procedures first
described more than half a century ago.14 All the synthetic
sequence can be scaled up to multigram quantities of the com-
pound 6, which can be prepared in a reasonable time
(1–2 weeks).
Easy synthetic availability of 6 prompted us to explore the
cyclooctyne ring construction first using this compound as a
model, and then applying the elaborated procedure to the
more complex and expensive DAE-derived bis-cyclooctyne pre-
cursor of 5, which could also be synthesized from 6.
The exocyclic alkene 9 was obtained from 6 in excellent
yield using the Wittig reaction. Rearrangement of 9 to the
corresponding cyclooctanone 10 proceeded smoothly under
action of hydroxy(tosyloxy)iodobenzene followed by aqueous-
methanol work-up, a procedure reported recently for
β-benzocycloalkenones.15 Formation of the enol triflate 11 fol-
lowed by elimination completed the synthesis of the model
cyclooctyne 12, in overall 18% yield.
We were pleased to find that compound 12 was highly reac-
tive in SPAAC, yet stable enough to allow performing the reac-
tion with azides in situ at ambient temperature. Although
attempts at isolating of pure 12 failed in our hands due to
Fig. 2 The cross-linking reagents (1–3), a pyrrole-containing cyclooc-
tyne (4) described in the literature and the new reagent developed in
this work (5).
Fig. 3 Strain-promoted azide–alkyne cycloaddition (SPAAC) reaction.
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compound decomposition, storage of this compound at
−20 °C in the solution after preparation preserved the com-
pound almost not degraded for several days. Reaction of 12
with benzyl azide proceeded completely in less than
30 minutes at 1 mM concentration and 0 °C giving isomeric
13a and 13b (syn : anti 24 : 76). Both triazole isomers were sep-
arated by preparative HPLC and their structure was assigned
through series of HMBC and NOESY 2D-NMR experiments (see
ESI†).
DFT calculations of the structure of 12 and its reaction with
methyl azide confirmed that the high reactivity of this com-
pound stems from the additional strain imposed by the five-
membered heterocycle fused to the cyclooctyne ring (Fig. 5).
Transition state activation barriers for SPAAC between 12
and methyl azide were calculated using Gaussian 0916 with the
B3LYP density functional and the 6-31 G(d) basis set within
the CPCM model for methanol as solvent at standard con-
ditions (see ESI† for full computational details). We found that
the activation barrier for the formation of the anti-regioisomer
(21.8 kcal mol−1) was lower than for the syn-regioisomer
(22.6 kcal mol−1), which is consistent with the experimental
observation of the anti-isomer being the predominant product
(Fig. 5a). Furthermore, the activation barrier for SPAAC with 12
(21.8 kcal mol−1) was found to be lower than the activation
barrier reported for both cyclooctyne 14 and benzocyclooctyne
Fig. 4 Synthesis of the model cyclooctyne 12 and its reaction with
benzyl azide.
Fig. 5 (a) Energy level diagram depicting SPAAC between 12 and
methyl azide in methanol (energy in kcal mol−1). (b) Calculated strain
energies and alkyne bond angles of 12, cyclooctyne 14, and benzo-
fused cyclooctyne 15.
Fig. 6 Synthesis of the target compound 5 and its SPAAC with benzyl
azide.
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15 (24.9 kcal mol−1),17 suggesting an increased reactivity. We
also calculated the strain energy for 12 (18.4 kcal mol−1) which
was found to be higher than the calculated strain energy of
cyclooctyne 14 (13.6 kcal mol−1) and benzocyclooctyne 15
(14.4 kcal mol−1), implying an increased reactivity due to the
fusion of the five-membered thiophene ring (Fig. 5b). This
increase in the ring strain due to the fused five-membered
thiophene ring was also reflected by the decreased alkyne
bond angles in 12 (151.1°, 156.7°) compared to 14 (157.4°,
157.5°) and 15 (155.1°, 157.2°).
With these encouraging results at hands, we performed the
synthesis of the target DAE-derived bis-cyclooctyne 5, also
starting from 6. The corresponding synthetic route is shown in
Fig. 6.
The cycloheptanone 6 was brominated, and the obtained
bromo-derivative 16 was converted (through alkene 17) into
the cyclooctanone 18, similarly to the transformation of 6 to
10 described above. The carbonyl group in 18 was protected to
allow synthesizing the DAE derivative 20 using the procedure
reported previously by Irie et al.18 Then the carbonyl groups
were liberated (forming compound 21). Formation of the enol
triflate (compound 22) followed by the HOTf elimination com-
pleted the synthesis of the DAE building block 5 in about 10%
overall yield, calculating on 6.
As expected, the bis-cyclooctyne 5 was as reactive as 12
towards benzyl azide, a colourless 23a was formed as a major
product in its SPAAC with benzyl azide (the storage of 12 after
the preparation should be done at −20 °C due to its relative
instability). Compound 23a was isolated in the open form and
fully characterized. Blue-coloured 23a(closed) was prepared
from the colourless 23a(open) by irradiation with UV light
(256 nm) and characterized; 23a(closed) could, in turn, be
transformed back to 23a(open) by irradiation with visible light
(590 nm). Both transformations proceeded in quantitative
yield, demonstrating a high eﬃciency of the photoconversion.
Notably, the conversion of 23a(closed) to 23a(open) can be
achieved by red light: the low-energy absorption band of the
closed isomer is intense enough at 630–650 nm (see the
UV-VIS absorption spectrum in Fig. 7a). This feature is impor-
tant for the application of the DAE-derived compounds in vivo,
because red light penetrates deeply into live tissues. Hence,
photocontrol of biologically active derivatives of 23 should be
feasible non-invasively as deep as 1–2 cm beneath the tissue
surface.19
The photoisomerization of 23a(closed) to 23a(open) pro-
ceeded within minutes (Fig. 7b), which is typical for DAEs.1a–d
Observation of a perfect isosbestic point (298 nm) confirmed
that no other chemical processes other than the photo-isomer-
ization took place during irradiation.
Finally, to check the utility of the new building block 5
for peptide stapling, we prepared a stapled version of a
peptide that originally stemmed from the PDI sequence
Fig. 8 Linear peptide used for stapling with 3 (ref. 8) and 5 (this work)
and its SPAAC products 25 and 26.
Fig. 7 (a) Photoisomerization of 23 and UV-VIS absorption spectra of
both photoforms; (b) kinetics of the photoconversion of 23a(closed) to
23a(open) (MeOH solution, C = 1 × 10−5 M, 25 °C) by irradiation with UV
light (256 nm) at ∼10 mW cm−2.
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(LTFEHYWAQLTS), which had been identified by phage
display as an eﬃcient inhibitor of p53/MDM2 and p53/MDMX
protein–protein interactions.20 These interactions are known
as important targets for anti-cancer drug candidates.21 Peptide
inhibitors of p53/MDM2 and p53/MDMX are among the most
promising compounds currently under investigation and
development.22 Recently, PDI analogues stapled by SPAAC
employing the cyclooctadiyne 3 as a linker have been pre-
pared.8 For one of the most potent MDM2 binders identified,
the linear precursor 24 bearing two azide-substituted side-
chains in positions (i,i + 7) was used to prepare a stapled
peptide 25 (Fig. 8). In this work, we also used precursor 24 to
prepare the DAE-modified stapled peptides.
SPAAC between 24 and the cross-linker 5 was performed at
1 mM concentration of both reactants and was found to be
complete within less than one hour (methanol, 25 °C, LCMS
monitoring of the reaction mixture). Three diﬀerent stapled
peptide isomers (of the general formula 26, Fig. 8) were easily
separated by preparative HPLC using standard chromato-
graphic approaches (see the ESI† for the details).
Conclusions
A novel DAE-derived bis-cyclooctyne 5 was synthesized for use
as a cross-linking reagent by SPAAC. The stable compound was
shown to be highly reactive towards azides due to additional
strain imposed on the cyclooctyne rings by the fused thio-
phene rings. The high azide reactivity of 5 makes it a useful
building block for azide cross-linking, e.g. for obtaining
stapled peptides, as demonstrated on a peptide inhibitor of
the p53/MDM2 and p53/MDMX protein–protein interactions.
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